Kyle B Fraser1, Mark S Moehle1, Roy N Alcalay1, Andrew B West2. 1. From the Center for Neurodegeneration and Experimental Therapeutics (K.B.F., M.S.M., A.B.W.), Department of Neurology, University of Alabama at Birmingham; and Department of Neurology (R.N.A.), Columbia University, New York, NY. 2. From the Center for Neurodegeneration and Experimental Therapeutics (K.B.F., M.S.M., A.B.W.), Department of Neurology, University of Alabama at Birmingham; and Department of Neurology (R.N.A.), Columbia University, New York, NY. abwest@uab.edu.
Abstract
OBJECTIVE: To test whether phosphorylated Ser-1292 LRRK2 levels in urine exosomes predicts LRRK2 mutation carriers (LRRK2+) and noncarriers (LRRK2-) with Parkinson disease (PD+) and without Parkinson disease (PD-). METHODS: LRRK2 protein was purified from urinary exosomes collected from participants in 2 independent cohorts. The first cohort included 14 men (LRRK2+/PD+, n = 7; LRRK2-/PD+, n = 4; LRRK2-/PD-, n = 3). The second cohort included 62 men (LRRK2-/PD-, n = 16; LRRK2+/PD-, n = 16; LRRK2+/PD+, n = 14; LRRK2-/PD+, n = 16). The ratio of Ser(P)-1292 LRRK2 to total LRRK2 was compared between LRRK2+/PD+ and LRRK2- in the first cohort and between LRRK2 G2019S carriers with and without PD in the second cohort. RESULTS: LRRK2+/PD+ had higher ratios of Ser(P)-1292 LRRK2 to total LRRK2 than LRRK2-/PD- (4.8-fold, p < 0.001) and LRRK2-/PD+ (4.6-fold, p < 0.001). Among mutation carriers, those with PD had higher Ser(P)-1292 LRRK2 to total LRRK2 than those without PD (2.2-fold, p < 0.001). Ser(P)-1292 LRRK2 levels predicted symptomatic from asymptomatic carriers with an area under the receiver operating characteristic curve of 0.844. CONCLUSION: Elevated ratio of phosphorylated Ser-1292 LRRK2 to total LRRK2 in urine exosomes predicted LRRK2 mutation status and PD risk among LRRK2 mutation carriers. Future studies may explore whether interventions that reduce this ratio may also reduce PD risk.
OBJECTIVE: To test whether phosphorylated Ser-1292 LRRK2 levels in urine exosomes predicts LRRK2 mutation carriers (LRRK2+) and noncarriers (LRRK2-) with Parkinson disease (PD+) and without Parkinson disease (PD-). METHODS:LRRK2 protein was purified from urinary exosomes collected from participants in 2 independent cohorts. The first cohort included 14 men (LRRK2+/PD+, n = 7; LRRK2-/PD+, n = 4; LRRK2-/PD-, n = 3). The second cohort included 62 men (LRRK2-/PD-, n = 16; LRRK2+/PD-, n = 16; LRRK2+/PD+, n = 14; LRRK2-/PD+, n = 16). The ratio of Ser(P)-1292 LRRK2 to total LRRK2 was compared between LRRK2+/PD+ and LRRK2- in the first cohort and between LRRK2G2019S carriers with and without PD in the second cohort. RESULTS:LRRK2+/PD+ had higher ratios of Ser(P)-1292 LRRK2 to total LRRK2 than LRRK2-/PD- (4.8-fold, p < 0.001) and LRRK2-/PD+ (4.6-fold, p < 0.001). Among mutation carriers, those with PD had higher Ser(P)-1292 LRRK2 to total LRRK2 than those without PD (2.2-fold, p < 0.001). Ser(P)-1292 LRRK2 levels predicted symptomatic from asymptomatic carriers with an area under the receiver operating characteristic curve of 0.844. CONCLUSION: Elevated ratio of phosphorylated Ser-1292 LRRK2 to total LRRK2 in urine exosomes predicted LRRK2 mutation status and PD risk among LRRK2 mutation carriers. Future studies may explore whether interventions that reduce this ratio may also reduce PD risk.
Authors: Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman Journal: N Engl J Med Date: 2006-01-26 Impact factor: 91.245
Authors: Philip J Webber; Archer D Smith; Saurabh Sen; Matthew B Renfrow; James A Mobley; Andrew B West Journal: J Mol Biol Date: 2011-07-22 Impact factor: 5.469
Authors: Andrew B West; Darren J Moore; Saskia Biskup; Artem Bugayenko; Wanli W Smith; Christopher A Ross; Valina L Dawson; Ted M Dawson Journal: Proc Natl Acad Sci U S A Date: 2005-11-03 Impact factor: 11.205
Authors: Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood Journal: Lancet Neurol Date: 2008-06-06 Impact factor: 44.182
Authors: Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser Journal: Neuron Date: 2004-11-18 Impact factor: 17.173
Authors: William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood Journal: Lancet Date: 2005 Jan 29-Feb 4 Impact factor: 79.321
Authors: Naheed L Khan; Shushant Jain; John M Lynch; Nicola Pavese; Patrick Abou-Sleiman; Janice L Holton; Daniel G Healy; William P Gilks; Mary G Sweeney; Milan Ganguly; Vaneesha Gibbons; Sonia Gandhi; Jenny Vaughan; Louise H Eunson; Regina Katzenschlager; Juliet Gayton; Graham Lennox; Tamas Revesz; David Nicholl; Kailash P Bhatia; Niall Quinn; David Brooks; Andrew J Lees; Mary B Davis; Paola Piccini; Andrew B Singleton; Nicholas W Wood Journal: Brain Date: 2005-11-04 Impact factor: 13.501
Authors: Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton Journal: Neuron Date: 2004-11-18 Impact factor: 17.173
Authors: Zhiyong Liu; Nicole Bryant; Ravindran Kumaran; Alexandra Beilina; Asa Abeliovich; Mark R Cookson; Andrew B West Journal: Hum Mol Genet Date: 2018-01-15 Impact factor: 6.150
Authors: Kyle B Fraser; Ashlee B Rawlins; Rachel G Clark; Roy N Alcalay; David G Standaert; Nianjun Liu; Andrew B West Journal: Mov Disord Date: 2016-10 Impact factor: 10.338
Authors: Alice S Chen-Plotkin; Roger Albin; Roy Alcalay; Debra Babcock; Vikram Bajaj; Dubois Bowman; Alex Buko; Jesse Cedarbaum; Daniel Chelsky; Mark R Cookson; Ted M Dawson; Richard Dewey; Tatiana Foroud; Mark Frasier; Dwight German; Katrina Gwinn; Xuemei Huang; Catherine Kopil; Thomas Kremer; Shirley Lasch; Ken Marek; Jarrod A Marto; Kalpana Merchant; Brit Mollenhauer; Anna Naito; Judith Potashkin; Alyssa Reimer; Liana S Rosenthal; Rachel Saunders-Pullman; Clemens R Scherzer; Todd Sherer; Andrew Singleton; Margaret Sutherland; Ines Thiele; Marcel van der Brug; Kendall Van Keuren-Jensen; David Vaillancourt; David Walt; Andrew West; Jing Zhang Journal: Sci Transl Med Date: 2018-08-15 Impact factor: 17.956
Authors: Asha Kishore; Ashwin Ashok Kumar Sreelatha; Marc Sturm; Felix von-Zweydorf; Lasse Pihlstrøm; Francesco Raimondi; Rob Russell; Peter Lichtner; Moinak Banerjee; Syam Krishnan; Roopa Rajan; Divya Kalikavil Puthenveedu; Sun Ju Chung; Peter Bauer; Olaf Riess; Christian Johannes Gloeckner; Rejko Kruger; Thomas Gasser; Manu Sharma Journal: Mov Disord Date: 2018-11-28 Impact factor: 10.338